Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, an established treatment for cancer patients, could offer a novel therapeutic approach to decrease levels of inflammation in the atherosclerotic plaques of patients with CVD reports an abstract study at the ICNC11, International Conference on Nuclear Cardiology and Cardiac CT. Read more